Advice
Following an abbreviated submission
Decapeptyl™ SR 11.25mg is accepted for use within NHS Scotland for the treatment of advanced prostate cancer in patients for whom the use of triptorelin is appropriate and who would benefit from reduced frequency of administration compared with Decapeptyl™ SR 3mg (every 3 months vs every 28 days).
Download detailed advice23KB (PDF)
Medicine details
- Medicine name:
- Decapeptyl SR 11.25 mg (Triptorelin acetate®)
- SMC ID:
- 109/04
- Indication:
- Advanced Prostate Cancer
- Pharmaceutical company
- Ipsen Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 12 July 2004